nual number of new treatments approved by the U.S. Food and Drug Administration (FDA) has remained relatively constant and limited7. A recent study estimated that pharmaceutical companies spent $2.6 billion in 2015, up from $802 million in 2003, in the development of an FDA-approved new chemical entity drug8. Drug repurposing, represented as an effective drug discovery strategy from existing d